跳到主要內容

很遺憾,我們無法支援你的瀏覽器。如果可以,請升級到新版本,或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更新版本。如果無法升級,而且需要支援,請將你的回饋寄給我們。

我們衷心感謝你對這個新體驗的回饋。告訴我們你的想法 打開新的分頁/視窗

Elsevier
與我們共同出版

Profile

Twan Lammers

TL

Twan Lammers

Talk Title: Strategies to Promote Cancer Nanomedicine Clinical Translation

University of Aachen (RWTH), Germany

Twan Lammers obtained a D.Sc. in Radiation Oncology from Heidelberg University in 2008 and a Ph.D. in Pharmaceutical Technology from Utrecht University in 2009. In the same year, he started the Nanomedicine and Theranostics group at RWTH Aachen University. In 2014, he was promoted to full professor of medicine at RWTH Aachen University Clinic. His group aims to individualize and improve disease treatment by combining drug targeting with imaging. To this end, image-guided (theranostic) drug delivery systems are being developed, as well as materials and methods to monitor tumor growth, angiogenesis, inflammation, fibrosis and metastasis. He has received multiple scholarships and awards, including ERC starting, consolidator and proof-of-concept grants, the CRS Young Investigator Award, the Adritelf International Award, the Belgian Society for Pharmaceutical Sciences International Award, and the JNB Trailblazer Award. He served as the president of the Controlled Release Society in 2023-2024, and he has been a council member of the European Society for Molecular Imaging for almost 10 years. He is a member of the editorial board of 10 journals, and acts as associate editor for JCR, DDTR and MIB. Since 2019, he is included in the Clarivate Analytics list of Highly Cited Researchers.

Recent Publications:

1. Bhatia S, Chen X, Dobrovolskaia M, Lammers T. Cancer nanomedicine. Nat Rev Cancer 22, 550-556 (2022)

2. Biancacci I, De Lorenzi F, Theek B, Bai X, May J, Consolino L, Baues M, Moeckel D, Gremse F, Stillfried S, El Shafei A, Benderski K, Shalmani A, Wang A, Momoh J, Pena Q, Buhl E, Buyel J, Hennink W, Kiessling F, Metselaar J, Shi Y, Lammers T. Monitoring EPR effect dynamics during nanotaxane treatment with theranostic polymeric micelles. Adv Sci e2103745 (2022)

3. Miedema I, Zwezerijnen G, Huisman M, Doeleman E, Mathijssen R, Lammers T, Hu Q, van Dongen G, Rijcken C, Vugts D, Menke C. PET‐CT Imaging of polymeric nanoparticle tumor accumulation in patients. Adv Mater 34: 2201043 (2022)

4. Dasgupta A, Sun T, Palomba R, Rama E, Zhang Y, Power C, Liu M, Sarode A, Weiler M, Motta A, Porte C, Magnuska Z, Elshafei A, Barmin R, Graham A, McClelland A, Rommel D, Stickeler E, Kiessling F, Pallares R, De Laporte L, Decuzzi P, McDannold N, Mitragotri S, Lammers T. Non-spherical ultrasound microbubbles. PNAS 120, e2218847120 (2023)

5. Dasgupta A, Sun T, Rama E, Motta A, Zhang Y, Power C, Moeckel D, Moosavifar M, Barmin R, Porte C, Buhl E, Bastard C, Pallares R, Kiessling F, McDannold N, Mitragotri S, Lammers T. Transferrin receptor-targeted nonspherical microbubbles for blood-brain barrier sonopermeation. Adv Mater 35, e2308150 (2023)

6. Sofias A, Lammers T. Multidrug nanomedicine. Nat Nanotechnol 18, 104-106 (2023)

7. Lammers T. Nanomedicine tumor targeting. Adv Mater 36: e2312169 (2024)

8. Dasgupta A, Sofias A, Kiessling F, Lammers T. Nanoparticle delivery to tumors: From EPR and ATR mechanisms to clinical impact. Nat Rev Bioeng 2: 714-716 (2024)

9. May J, Moss J, Mueller F, Golombek S, Biancacci I, Rizzo L, Gremse F, Pola R, Pechar M, Etrych T, Becker S, Trautwein C, Buelow R, Boor P, Knuechel R, Stilfried S, Storm G, Puri S, Barry S, Schulz V, Kiessling F, Ashford M, Lammers T. Histopathological biomarkers for predicting the tumour accumulation of nanomedicines. Nat Biomed Eng 8, 1366-1378 (2024)

10. Benderski K, Lammers T, Sofias A. Analysis of multidrug cancer nanomedicine. Nat Nanotechnol (in press)